136 related articles for article (PubMed ID: 37772579)
1. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus.
Nakayama Y; Enomoto D; Yamamoto K; Takara K
Anticancer Res; 2023 Oct; 43(10):4349-4357. PubMed ID: 37772579
[TBL] [Abstract][Full Text] [Related]
2. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
3. Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?
Nogueira I; Dias F; Morais M; Teixeira AL; Medeiros R
Future Oncol; 2019 Jul; 15(20):2361-2370. PubMed ID: 31267758
[No Abstract] [Full Text] [Related]
4. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitors in advanced renal cell carcinoma.
Voss MH; Molina AM; Motzer RJ
Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
8. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
9. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
10. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.
Li X; Hou G; Zhu Z; Yan F; Wang F; Wei D; Zheng Y; Yuan J; Zheng W; Zhang G; Meng P; Guo Y; Li X; Yao L; Shen L; Yuan J
Invest New Drugs; 2020 Aug; 38(4):956-966. PubMed ID: 31463638
[TBL] [Abstract][Full Text] [Related]
11. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.
Hagiwara N; Watanabe M; Iizuka-Ohashi M; Yokota I; Toriyama S; Sukeno M; Tomosugi M; Sowa Y; Hongo F; Mikami K; Soh J; Fujito A; Miyashita H; Morioka Y; Miki T; Ukimura O; Sakai T
Cancer Lett; 2018 Sep; 431():182-189. PubMed ID: 29778569
[TBL] [Abstract][Full Text] [Related]
12. Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma.
Yangyun W; Guowei S; Shufen S; Jie Y; Rui Y; Yu R
Gene; 2022 Jan; 809():145992. PubMed ID: 34648917
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
[TBL] [Abstract][Full Text] [Related]
14. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
16. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors.
Rua Fernández OR; Escala Cornejo R; Navarro Martín M; García Muñoz M; Antunez Plaza P; García Dominguez AR; Cruz Hernández JJ
Urology; 2018 Jul; 117():41-43. PubMed ID: 29702156
[TBL] [Abstract][Full Text] [Related]
17. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
18. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
19. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Holland WS; Tepper CG; Pietri JE; Chinn DC; Gandara DR; Mack PC; Lara PN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):185-94. PubMed ID: 21644050
[TBL] [Abstract][Full Text] [Related]
20. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
